Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion

Acta Ophthalmologica

Volumn 90, Issue 2, 2012, Pages

  Koss, Michael J ^a   Pfister, Marcel ^a   Rothweiler, Florian ^b   Michaelis, Martin ^b   Cinatl, Jindrich ^b   Schubert, Ralf ^b   Koch, Frank H ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

cytometric bead array; interleukin 6; monocyte chemoattractant protein; retinal vein occlusion; vascular endothelial growth factor; vitreous samples

Indexed keywords

BEVACIZUMAB; CYTOKINE; DEXAMETHASONE; DEXARATIOPHARM; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

AGED; ARTICLE; BRANCH RETINA VEIN OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CULTURE TECHNIQUE; CYTOMETRY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HEMI CENTRAL RETINA VEIN OCCLUSION; HUMAN; HUMAN TISSUE; IMMUNOPATHOGENESIS; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; UNDILUTED VITREOUS; VITRECTOMY; VITREOUS BODY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHEMOKINE CCL2; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; FLUORESCEIN ANGIOGRAPHY; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN-6; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; RETINAL VEIN OCCLUSION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY; VITREOUS BODY;

EID: 84857784587     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2011.02292.x     Document Type: Article

References (30)

1. Cohen T, Nahari D, Cerem LW, Neufeld G, &, Levi BZ, (1996): Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271: 736-741. (Pubitemid 26034921)
2. Ehrlich R, Ciulla TA, Moss AM, &, Harris A, (2010): Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up. Graefes Arch Clin Exp Ophthalmol 248: 375-380.
3. Eickmeier O, Huebner M, Herrmann E, et al., (2010): Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function. Cytokine 50: 152-157.
4. Funk M, Kriechbaum K, Prager F, Benesch T, Georgopoulos M, Zlabinger GJ, &, Schmidt-Erfurth U, (2009): Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 50: 1025-1032.
5. Hong KH, Ryu J, &, Han KH, (2005): Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood 105: 1405-1407. (Pubitemid 40223654)
6. Hoshino M, Takahashi M, &, Aoike N, (2001): Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J Allergy Clin Immunol 107: 295-301. (Pubitemid 32173907)
7. Jo N, Wu GS, &, Rao NA, (2003): Upregulation of chemokine expression in the retinal vasculature in ischemia-reperfusion injury. Invest Ophthalmol Vis Sci 44: 4054-4060. (Pubitemid 37047982)
8. Kaneda S, Miyazaki D, Sasaki SI, et al., (2011): Multivariate analyses of inflammatory cytokines in eyes with branch retinal vein occlusion: relationships to bevacizumab treatment. Invest Ophthalmol Vis Sci [Epub ahead of print].
9. Koss MJ, Naser H, Sener A, Ackermann H, Al-Sarireh F, Singh P, &, Koch FH, (2010): Combination therapy in diabetic macular oedema and retinal vein occlusion-past and present. Acta Ophthalmol [Epub ahead of print].
10. Maier R, Weger M, Haller-Schober EM, El-Shabrawi Y, Theisl A, Barth A, Aigner R, &, Haas A, (2006): Application of multiplex cytometric bead array technology for the measurement of angiogenic factors in the vitreous. Mol Vis 12: 1143-1147. (Pubitemid 44509623)
11. Mandelcorn E, Khan Y, Javorska L, Cohen J, Howarth D, &, Mandelcorn M, (2003): Idiopathic epiretinal membranes: cell type, growth factor expression, and fluorescein angiographic and retinal photographic correlations. Can J Ophthalmol 38: 457-463. (Pubitemid 37465963)
12. Morgan E, Varro R, Sepulveda H, et al., (2004): Cytometric bead array: a multiplexed assay platform with applications in various areas of biology. Clin Immunol 110: 252-266. (Pubitemid 38402005)
13. Noma H, Funatsu H, Yamasaki M, et al., (2008): Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye (Lond) 22: 42-48.
14. Noma H, Funatsu H, Mimura T, Harino S, &, Hori S, (2009): Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology 116: 87-93.
15. Noma H, Funatsu H, Mimura T, Harino S, &, Hori S, (2010): Aqueous humor levels of vasoactive molecules correlate with vitreous levels and macular edema in central retinal vein occlusion. Eur J Ophthalmol 20: 402-409.
16. Noma H, Funatsu H, Mimura T, Eguchi S, &, Shimada K, (2011a): Role of soluble vascular endothelial growth factor receptor-2 in macular oedema with central retinal vein occlusion. Br J Ophthalmol 95: 788-792.
17. Noma H, Funatsu H, Mimura T, Eguchi S, Shimada K, &, Hori S, (2011b): Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Curr Eye Res 36: 256-263.
18. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, &, Keshet E, (1998): Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 105: 412-416. (Pubitemid 28125092)
19. Prager F, Michels S, Kriechbaum K, Georgopoulos M, Funk M, Geitzenauer W, Polak K, &, Schmidt-Erfurth U, (2009): Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 93: 452-456.
20. Ryan SJ, (2006): Retina, 4th Edn. Philadelphia: MOSBY. 2645ff.
21. Schober A, &, Zernecke A, (2007): Chemokines in vascular remodeling. Thromb Haemost 97: 730-737. (Pubitemid 46779958)
22. Shahid H, Hossain P, &, Amoaku WM, (2006): The management of retinal vein occlusion: is interventional ophthalmology the way forward? Br J Ophthalmol 90: 627-639.
23. Stefansson E, (2008): Treatment of branch retinal vein occlusion. Acta Ophthalmol 86: 122-123.
24. Stefansson E, &, Loftsson T, (2006): The Stokes-Einstein equation and the physiological effects of vitreous surgery. Acta Ophthalmol Scand 84: 718-719. (Pubitemid 44688317)
25. The Eye Disease Case-Control Study Group (1993): Risk factors for branch retinal vein occlusion. The Eye Disease Case-Control Study Group. Am J Ophthalmol 116: 286-296.
26. The Eye Disease Case-Control Study Group (1996): Risk factors for central retinal vein occlusion. The Eye Disease Case-Control Study Group. Arch Ophthalmol 114: 545-554.
27. Tsujikawa A, Sakamoto A, Ota M, Kotera Y, Oh H, Miyamoto K, Kita M, &, Yoshimura N, (2010): Serous retinal detachment associated with retinal vein occlusion. Am J Ophthalmol 149: 291-301 e295.
28. Wong DT, Elovic A, Matossian K, et al., (1991): Eosinophils from patients with blood eosinophilia express transforming growth factor beta 1. Blood 78: 2702-2707.
29. Yamaike N, Tsujikawa A, Ota M, et al., (2008): Three-dimensional imaging of cystoid macular edema in retinal vein occlusion. Ophthalmology 115: 355-362.
30. Yoshimura T, Sonoda KH, Sugahara M, et al., (2009): Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS ONE 4: e8158.